Søren Maarssø

Søren Maarssø serves as Chair of the Board of Directors of TETRAPHARM, a Copenhagen-based biopharmaceutical company focused on developing drug candidates targeting the central nervous system and the immune system, while providing contract development and manufacturing services to pharmaceutical partners. TETRAPHARM's proprietary drug delivery technology, ZYNDIKATE®, enables the development and scale-up of robust formulations for challenging molecules, including poorly water soluble molecules.

Maarssø brings extensive operational experience to the role. His career spans over 23 years and he is registered as owning 22 Danish companies, placing him in the top 1 percent of business owners in Denmark. He held leadership positions at TRESU A/S from 2013-2018, serving as director, and also served as administrative director of Tresu Group Holding A/S and Tresu Investment Holding A/S from 2017-2018. Earlier, he began his business career in 2003 as a board member and director at TRESU A/S.

Career History

• Director at Maarssø Invest ApS (2019–present)
• Administrative Director, Tresu Group Holding A/S and Tresu Investment Holding A/S (2017–2018)
• Director at TRESU A/S (2013–2018)
• Board member and director at TRESU A/S (2003–2008)
• Board member at Holtec A/S (2020–present)

What Maarssø could bring to TETRAPHARM: His demonstrated experience scaling manufacturing operations at TRESU A/S—where he oversaw 264 employees in 2018—positions him well to support TETRAPHARM's contract development and manufacturing services expansion. His extensive track record in building and managing portfolio companies, combined with his tenure in operational roles within production-focused enterprises, suggests capacity to navigate the complex commercial and operational challenges facing a biotech firm balancing proprietary drug development with CDMO services.